EC
AXSM icon

EntryPoint Capital’s Axsome Therapeutics AXSM Stock Holding History

EntryPoint Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Buy
+1,391
New +$302K 0.08% 493
2025
Q4 		– Sell
-2,263
Closed -$275K – 665
2025
Q3 		$275K Buy
2,263
+176
+8% +$19.8K 0.11% 400
2025
Q2 		$218K Sell
2,087
-80
-4% -$8.47K 0.11% 444
2025
Q1 		$253K Buy
+2,167
New +$247K 0.12% 427
2024
Q4 		– Sell
-5,156
Closed -$463K – 724
2024
Q3 		$463K Buy
5,156
+4,985
+2,915% +$435K 0.26% 74
2024
Q2 		$13.8K Sell
171
-266
-61% -$19.7K 0.01% 1274
2024
Q1 		$34.9K Buy
+437
New +$36.7K 0.03% 910

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EntryPoint Capital's AXSM Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,391 shares worth $340K. The stake represents 0.08% of the portfolio and ranks #493 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in AXSM as recently as Q3 2025.

EntryPoint Capital first reported a position in AXSM in Q1 2024 and has held it in 7 quarters since. The position peaked at $463K in Q3 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • EntryPoint Capital held 1,391 shares of Axsome Therapeutics worth $340K as of Q2 2026.
  • Axsome Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Axsome Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #493 holding.
  • EntryPoint Capital first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • EntryPoint Capital's Axsome Therapeutics position peaked at $463K in Q3 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.